Article info
Multiple sclerosis
Short report
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
- Correspondence to Dr Joanne Jones, Department of Clinical Neurosciences, University of Cambridge, Box 165, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Jls53{at}medschl.cam.ac.uk.
Citation
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
Publication history
- Received October 16, 2013
- Revised November 28, 2013
- Accepted November 28, 2013
- First published December 24, 2013.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions